{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tetanus+Immune+Globulin+%28Human%29", "query": { "intervention": "Tetanus Immune Globulin (Human)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T20:41:20.929Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00437671", "title": "Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Tetanus" ], "interventions": [ { "name": "Tetanus Immune Globulin (Human)", "type": "DRUG" }, { "name": "Diphtheria-Tetanus Toxoids Adsorbed", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 6, "start_date": "2007-03", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-10-02T20:41:20.929Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00437671" }, { "nct_id": "NCT00359983", "title": "Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neisseria Meningitidis", "Haemophilus Influenzae Type b" ], "interventions": [ { "name": "MenHibrix (Hib-MenCY-TT)", "type": "BIOLOGICAL" }, { "name": "Hib conjugate vaccine (ActHIB)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "22 Months", "maximum_age": "60 Months", "sex": "ALL", "summary": "22 Months to 60 Months" }, "enrollment_count": 270, "start_date": "2006-09", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2016-12-16", "last_synced_at": "2026-10-02T20:41:20.929Z", "location_count": 21, "location_summary": "Little Rock, Arkansas • Fountain Valley, California • Norwich, Connecticut + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Woodstock", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00359983" }, { "nct_id": "NCT02366728", "title": "DC Migration Study for Newly-Diagnosed GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Astrocytoma, Grade IV", "Giant Cell Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Unpulsed DCs", "type": "BIOLOGICAL" }, { "name": "Td", "type": "BIOLOGICAL" }, { "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs", "type": "BIOLOGICAL" }, { "name": "111In-labeled DCs", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 64, "start_date": "2015-10-12", "completion_date": "2020-10-31", "has_results": true, "last_update_posted_date": "2023-06-08", "last_synced_at": "2026-10-02T20:41:20.929Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02366728" }, { "nct_id": "NCT03562377", "title": "Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tdap vaccine", "type": "BIOLOGICAL" }, { "name": "Meningococcal vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "54 Years", "sex": "ALL", "summary": "18 Years to 54 Years" }, "enrollment_count": 215, "start_date": "2018-07-13", "completion_date": "2019-11-22", "has_results": true, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-10-02T20:41:20.929Z", "location_count": 39, "location_summary": "Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03562377" }, { "nct_id": "NCT02864368", "title": "Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "5-day TMZ", "type": "DRUG" }, { "name": "21-day TMZ", "type": "DRUG" }, { "name": "PEP-CMV: Component A", "type": "BIOLOGICAL" }, { "name": "Tetanus-Diphtheria booster", "type": "DRUG" }, { "name": "Tetanus Pre-Conditioning", "type": "DRUG" }, { "name": "PEP-CMV: Component B", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Eric Thompson, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-12-07", "completion_date": "2020-06-15", "has_results": true, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-02T20:41:20.929Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02864368" }, { "nct_id": "NCT00004735", "title": "The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tetanus toxoid", "type": "BIOLOGICAL" }, { "name": "Hepatitis A Vaccine (Inactivated)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "2 Years to 24 Years" }, "enrollment_count": 81, "start_date": "2000-02", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2013-10-07", "last_synced_at": "2026-10-02T20:41:20.929Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Alhambra", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004735" }, { "nct_id": "NCT03688178", "title": "DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Varlilumab", "type": "BIOLOGICAL" }, { "name": "Td", "type": "BIOLOGICAL" }, { "name": "Unpulsed DCs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Annick Desjardins, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2020-08-26", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-02T20:41:20.929Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03688178" } ] }